Loading...
Loading...
GARP Research & Securities lowers its rating on Cepheid
CPHD from Buy to Neutral, with a newly-announced $38 price target.
GARP Research & Securities notes, "The company's mainstay assays are increasing in volume,
pipeline tests are advancing, and the installed base of GeneXpert systems continues to expand. However, the company is priced for perfection, in our opinion, and while the fundamental story continues improving, we think any misstep could bring about a strong technical correction."
CPHD closed at $38.07 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorDowngradesPrice TargetIntraday UpdateAnalyst RatingsGARP Research & Securities
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in